146 related articles for article (PubMed ID: 15883971)
1. Chemoenzymatic synthesis of HIV-1 gp41 glycopeptides: effects of glycosylation on the anti-HIV activity and alpha-helix bundle-forming ability of peptide C34.
Wang LX; Song H; Liu S; Lu H; Jiang S; Ni J; Li H
Chembiochem; 2005 Jun; 6(6):1068-74. PubMed ID: 15883971
[TBL] [Abstract][Full Text] [Related]
2. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
Gustchina E; Hummer G; Bewley CA; Clore GM
J Med Chem; 2005 Apr; 48(8):3036-44. PubMed ID: 15828842
[TBL] [Abstract][Full Text] [Related]
3. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
Gallo SA; Sackett K; Rawat SS; Shai Y; Blumenthal R
J Mol Biol; 2004 Jun; 340(1):9-14. PubMed ID: 15184018
[TBL] [Abstract][Full Text] [Related]
4. Functional and structural characterization of HIV-1 gp41 ectodomain regions in phospholipid membranes suggests that the fusion-active conformation is extended.
Korazim O; Sackett K; Shai Y
J Mol Biol; 2006 Dec; 364(5):1103-17. PubMed ID: 17045292
[TBL] [Abstract][Full Text] [Related]
5. Characterization of HIV-1 resistance to a fusion inhibitor, N36, derived from the gp41 amino-terminal heptad repeat.
Izumi K; Nakamura S; Nakano H; Shimura K; Sakagami Y; Oishi S; Uchiyama S; Ohkubo T; Kobayashi Y; Fujii N; Matsuoka M; Kodama EN
Antiviral Res; 2010 Aug; 87(2):179-86. PubMed ID: 20438763
[TBL] [Abstract][Full Text] [Related]
6. A template-assembled model of the N-peptide helix bundle from HIV-1 Gp-41 with high affinity for C-peptide.
Xu W; Taylor JW
Chem Biol Drug Des; 2007 Oct; 70(4):319-28. PubMed ID: 17937777
[TBL] [Abstract][Full Text] [Related]
7. Chemoenzymatic synthesis of HIV-1 V3 glycopeptides carrying two N-glycans and effects of glycosylation on the peptide domain.
Li H; Li B; Song H; Breydo L; Baskakov IV; Wang LX
J Org Chem; 2005 Nov; 70(24):9990-6. PubMed ID: 16292832
[TBL] [Abstract][Full Text] [Related]
8. Design and evaluation of antiretroviral peptides corresponding to the C-terminal heptad repeat region (C-HR) of human immunodeficiency virus type 1 envelope glycoprotein gp41.
Soonthornsata B; Tian YS; Utachee P; Sapsutthipas S; Isarangkura-na-Ayuthaya P; Auwanit W; Takagi T; Ikuta K; Sawanpanyalert P; Kawashita N; Kameoka M
Virology; 2010 Sep; 405(1):157-64. PubMed ID: 20580393
[TBL] [Abstract][Full Text] [Related]
9. Stronger anti-HIV-1 activity of C-peptide derived from HIV-1 89.6 gp41 C-terminal heptad repeated sequence.
Seo JK; Kim HK; Lee TY; Hahm KS; Kim KL; Lee MK
Peptides; 2005 Nov; 26(11):2175-81. PubMed ID: 15876473
[TBL] [Abstract][Full Text] [Related]
10. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions.
Nameki D; Kodama E; Ikeuchi M; Mabuchi N; Otaka A; Tamamura H; Ohno M; Fujii N; Matsuoka M
J Virol; 2005 Jan; 79(2):764-70. PubMed ID: 15613304
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.
Lu L; Tong P; Yu X; Pan C; Zou P; Chen YH; Jiang S
Biochim Biophys Acta; 2012 Dec; 1818(12):2950-7. PubMed ID: 22867851
[TBL] [Abstract][Full Text] [Related]
12. The hydrophobic pocket contributes to the structural stability of the N-terminal coiled coil of HIV gp41 but is not required for six-helix bundle formation.
Dwyer JJ; Hasan A; Wilson KL; White JM; Matthews TJ; Delmedico MK
Biochemistry; 2003 May; 42(17):4945-53. PubMed ID: 12718536
[TBL] [Abstract][Full Text] [Related]
13. Enzymatic glycosylation of triazole-linked GlcNAc/Glc-peptides: synthesis, stability and anti-HIV activity of triazole-linked HIV-1 gp41 glycopeptide C34 analogues.
Huang W; Groothuys S; Heredia A; Kuijpers BH; Rutjes FP; van Delft FL; Wang LX
Chembiochem; 2009 May; 10(7):1234-42. PubMed ID: 19353609
[TBL] [Abstract][Full Text] [Related]
14. Expression and biochemical analysis of the entire HIV-2 gp41 ectodomain: determinants of stability map to N- and C-terminal sequences outside the 6-helix bundle core.
Lay CS; Wilson KA; Kobe B; Kemp BE; Drummer HE; Poumbourios P
FEBS Lett; 2004 Jun; 567(2-3):183-8. PubMed ID: 15178320
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation.
Kliger Y; Shai Y
J Mol Biol; 2000 Jan; 295(2):163-8. PubMed ID: 10623516
[TBL] [Abstract][Full Text] [Related]
16. Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells.
Otaka A; Nakamura M; Nameki D; Kodama E; Uchiyama S; Nakamura S; Nakano H; Tamamura H; Kobayashi Y; Matsuoka M; Fujii N
Angew Chem Int Ed Engl; 2002 Aug; 41(16):2937-40. PubMed ID: 12203417
[No Abstract] [Full Text] [Related]
17. [Inhibitory effect of polysaccharides on the six-alpha-helix bundle formation of HIV gp41 protein].
Wen XY; Wu SY; Xu W; Lv L; Liu SW; Rao JJ; Zhang JJ; Wang GF; Wan SH; Wu SG
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Oct; 27(10):1498-500. PubMed ID: 17959523
[TBL] [Abstract][Full Text] [Related]
18. N36, a synthetic N-terminal heptad repeat domain of the HIV-1 envelope protein gp41, is an activator of human phagocytes.
Le Y; Jiang S; Hu J; Gong W; Su S; Dunlop NM; Shen W; Li B; Ming Wang J
Clin Immunol; 2000 Sep; 96(3):236-42. PubMed ID: 10964542
[TBL] [Abstract][Full Text] [Related]
19. Identification of the HIV-1 gp41 core-binding motif--HXXNPF.
Huang JH; Liu ZQ; Liu S; Jiang S; Chen YH
FEBS Lett; 2006 Sep; 580(20):4807-14. PubMed ID: 16904109
[TBL] [Abstract][Full Text] [Related]
20. Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.
Deng Y; Zheng Q; Ketas TJ; Moore JP; Lu M
Biochemistry; 2007 Apr; 46(14):4360-9. PubMed ID: 17371053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
